Company Overview and News

1
Iovance Biotherapeutics upgraded to buy from neutral at B. Riley

2018-04-10 marketwatch
Biolife Solutions - Solid Close To 2017 And Off To Strong Start In 2018; Significant Opportunity Lies Ahead
Upvote Downvote

1
BLFS / BioLife Solutions, Inc. FORM DEF 14A

2018-04-06 sec.gov
bioli20180330_def14a.htm Table of Contents
Upvote Downvote

 
Your Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes' Setback, BioLife Preliminary Q1 Results

2018-04-03 seekingalpha
After a sell-off last week, MediciNova (NASDAQ:MNOV) shares have bounced back sharply in trading today as the company announced that it is terminating a phase 2 study of MN-001 in NASH and NAFLD with hypertriglyceridemia early based on the significant positive results from an interim analysis.
Upvote Downvote

 
Biolife Solutions - Solid Close To 2017 And Off To Strong Start In 2018; Significant Opportunity Lies Ahead

2018-03-29 seekingalpha
Sales growth of 34%/28% in FY2017/FY2016 achieved without any real impact from customer drug approvals; two customer approvals in 2H2017 and 15-20 Phase 3 trials bode well for future outlook.
Upvote Downvote

 
BLFS / BioLife Solutions, Inc. AMENDMENT NO. 2

2018-03-21 sec.gov
As filed with the Securities and Exchange Commission on March 21, 2018 Registration No. 333-222433
Upvote Downvote

1
BLFS / BioLife Solutions, Inc. FORM 10-K (Annual Report)

2018-03-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMIS
Upvote Downvote

 
BioLife Solutions' (BLFS) CEO Mike Rice on Q4 2017 Results - Earnings Call Transcript

2018-03-09 seekingalpha
BioLife Solutions Inc. (NASDAQ:BLFS) Q4 2017 Results Earnings Conference Call March 8, 2018 4:30 PM ET
Upvote Downvote

1
BLFS / BioLife Solutions, Inc. FORM 8-K (Current Report)

2018-03-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

3
Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

2018-02-15 seekingalpha
Today we will focus on Achaogen (AKAO), which got a slight boost after Tetraphase Pharma’s (TTPH) drug failed to beat ertapenem in a late-stage cUTI study.
Upvote Downvote

 
BLFS / BioLife Solutions, Inc. FORM 8-K (Current Report)

2018-02-12 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 12, 2018   BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter)   Delaware   001-36362   94-3076866 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

2
Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

2018-02-08 seekingalpha
Gilead/Kite, Iovance Biotherapeutics, bluebird bio, TiGenix, TissueGene, Adaptimmune and many more companies plus elite research institutions utilize its products.
Upvote Downvote

1
BLFS / BioLife Solutions, Inc. AMENDMENT NO. 1

2018-02-05 sec.gov
  As filed with the Securities and Exchange Commission on February 5, 2018   Registration No. 333-222433       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   AMENDMENT NO. 1 TO FORM S-3   REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   BioLife Solutions, Inc. (Exact name of registrant as specified in its charter)       Delaware 94-3076866 (State or other jurisdiction of (I.
Upvote Downvote

 
BLFS / BioLife Solutions, Inc. FORM 8-K (Current Report)

2018-01-26 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 22, 2018   BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter)   Delaware   001-36362   94-3076866 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
BLFS / BioLife Solutions, Inc. FORM S-8

2018-01-05 sec.gov
  As filed with the Securities and Exchange Commission on January 5, 2018 Registration No. 333-              UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933       BioLife Solutions, Inc. (Exact Name of Registrant as Specified in its Charter)     Delaware   94-3076866 (State or Other Jurisdiction of Incorporation or Organization)   (I.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 09062W204